Gluconeogenesis pathway proteins (GNG pathway proteins)

Gluconeogenesis pathway proteins encompass a group of enzymes responsible for the de novo synthesis of glucose from non-carbohydrate precursors such as lactate, glycerol, and glucogenic amino acids (LibreTexts, 2026; NIH, 2023). Key enzymes in this pathway include pyruvate carboxylase, phosphoenolpyruvate carboxykinase (PEPCK), fructose-1,6-bisphosphatase (FBPase), and glucose-6-phosphatase (G6Pase) (Wikipedia, 2026; NIH, 2023). These proteins play a critical role in maintaining blood glucose levels during fasting and are frequently overactive in type 2 diabetes, contributing to fasting hyperglycemia (NIH, 2023; ACS, 2007). Consequently, they are major therapeutic targets for anti-diabetic drugs like metformin, which suppresses the pathway through multiple mechanisms including AMPK activation and mitochondrial inhibition (NIH, 2022; YouTube/MedToday, 2024). Beyond metabolic disease, these enzymes are increasingly recognized for their roles in cancer metabolism, where they may be upregulated to support tumor growth or downregulated to facilitate the Warburg effect (Frontiers, 2023; ResearchGate, 2019).

Other names

Gluconeogenic enzymesHepatic glucose production enzymesGNG enzymes

Inhibition of key rate-limiting enzymes (FBPase, PEPCK, G6Pase) or suppression of their gene expression (via AMPK activation) to reduce hepatic glucose production (NIH, 2023; ACS, 2007; YouTube/MedToday, 2024).